Evidence map›Paper›PMID 35387237›Full record

ArticleTherapeutic advances in ophthalmology

Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study.

Sadhana Sharma, Pratap Karki, Sagun Narayan Joshi, Sanket Parajuli

Open access · diamondAbstract read
In one paragraph

Article in Therapeutic advances in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sadhana SharmaOphthalmologist, Mechi Eye Hospital, Jhapa 57200, Nepal.ORCID https://orcid.org/0000-0002-0550-6938
Pratap KarkiDepartment of Retina, B.P. Koirala Lions Center for Ophthalmic Studies (BPKLCOS), Institute of Medicine, Kathmandu, Nepal.
Sagun Narayan JoshiDepartment of Retina, B.P. Koirala Lions Center for Ophthalmic Studies (BPKLCOS), Institute of Medicine, Kathmandu, Nepal.
Sanket ParajuliReiyukai Eiko Masunaga Eye Hospital, Banepa, Nepal.
B.P. Koirala Institute of Health Sciences · NPTilganga Institute of Ophthalmology · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The purpose of this study was to evaluate the short-term response of intravitreal bevacizumab in diabetic macular edema (DME) and assess the variation in treatment outcomes in different morphology patterns using spectral domain-optical coherence tomography (SD-OCT). Objective: To study different morphological patterns of DME based on OCT and compare their treatment response to bevacizumab. Methods: Hundred and twelve eyes of 112 patients with DME were included and treated with intravitreal bevacizumab (1.25 mg/0.05 ml monthly for 3 months). The morphological patterns of DME were classified on the basis of OCT into three groups - diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD) - and changes in central macular thickness (CMT) and best corrected visual acuity (BCVA) after treatment were compared. Results: A total of 112 eyes with DME were included and consisted of 40 DRT, 37 CME, and 35 SRD. Treatment with bevacizumab resulted in decrease in central macular thickness and improvement in BCVA in all three groups. The baseline visual acuity and CMT of DRT group was better than that of the other two groups. The treatment outcome was measured in terms of CMT and BCVA. Change in CMT was statistically significant among three groups and was found to be better in DRT group ( Conclusion: Anatomic and visual improvement can be achieved by bevacizumab in all patterns of DME. However, individual pattern may respond differently. DRT, which appears to be the earliest form of DME, responds better than other types. Thus, the pattern of macular edema shown by OCT may provide an objective guideline in predicting the response of bevacizumab injection in DME.

Indexed as

bevacizumabdiabetic macular edemaOCT

Identifiers

PMID35387237
PMCPMC8977703
OpenAlexW4225968295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.